Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.
Raquel Laza-BriviescaAlberto Cruz-BermúdezErnest NadalAmelia InsaMaría Del Rosario García-CampeloGerardo HuidobroManuel DómineMargarita Majem TarruellaDelvys Rodriguez AbreuAlex Martinez-MartiJavier De Castro CarpeñoManuel CoboGuillermo López-VivancoElvira Del BarcoReyes BernabéNuria ViñolasIsidoro Barneto ArandaSantiago ViteriBartomeu MassutiMarta CasarrubiosBelén Sierra-RoderoCarlos TarínAránzazu García-GrandeCara L HaymakerIgnacio I WistubaAtocha RomeroFernando F FrancoMariano Provencio PullaPublished in: Clinical and translational medicine (2022)
Patients achieving CPR seem to have a distinctive peripheral blood immune status at diagnosis, even showing different immune response to treatment. These results reinforce the different biology behind CPR and non-CPR responses.
Keyphrases
- cardiac arrest
- cardiopulmonary resuscitation
- peripheral blood
- clinical trial
- end stage renal disease
- small cell lung cancer
- ejection fraction
- newly diagnosed
- rectal cancer
- peritoneal dialysis
- prognostic factors
- lymph node
- squamous cell carcinoma
- locally advanced
- randomized controlled trial
- radiation therapy
- advanced non small cell lung cancer
- open label
- phase ii
- double blind
- brain metastases
- placebo controlled